Novo Nordisk revealed last week that its recently-announced Beijing (diabetes) R&D center expansion has a budget of USD 100 million – with up to USD 40 million earmarked for new labs that should be operational by the end of 2011. Novo also released results of a 3-month survey undertaken with the Chinese Medical Association involving over 5,900 subjects with Type II diabetes, which revealed a high number of patients with poorly controlled blood glucose levels and a high prevalence of diabetic complications.